Strategic Acquisition IDS is part of Revvity and aligned with Euroimmun, suggesting access to a broader global sales network, larger customer base, and expanded product offerings that can be leveraged to upsell IDS immunoassay panels and automated systems.

Integrated Solutions Leveraging the IDS-iSYS automated platform combined with Euroimmun’s diagnostics portfolio presents an opportunity to offer integrated immunoassay solutions, cross-sell complementary panels, and bundled service agreements to clinical labs.

Growth Markets The company targets in vitro diagnostics with endocrinology and related panels; pursuing laboratories expanding automated testing capabilities and cortisol/IgG SARS‑CoV‑2 testing could yield demand for updated assays and new trackable panels.

Global Reach IDS operates within the UK and has multinational exposure via Revvity; a focused outreach to regional distributors and large reference labs in Europe and North America could accelerate adoption of iSYS assays and Cortisol tests.

Quality & Readiness ISO 9001 certification and established manufacturing capabilities indicate a reliable supplier; positioning IDS as a compliant, quality-focused partner can ease procurement for budget-conscious labs seeking stable supply and ongoing support.